Oxford's COVID-19 vaccine has shown a positive result in its initial trial. According to a report published in the British medical journal, The Lancet, the COVID-19 vaccine produced a dual immune response in people aged 18 to 55.Officially known as AZD1222, this COVID-19 vaccine candidate has been developed by the University of Oxford and British-Swedish pharmaceutial company AstraZeneca Plc.
The large-scale phase III human trials of Oxford COVID-19 vaccine has already started in Brazil.AstraZeneca has joined Serum Institute of India (SII), the world's largest vaccine manufacturers by number of doses produced and sold, to produce the potential vaccine.
Read more on livemint.com